These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 23118295)
1. Lower 12-hour trough concentrations of mycophenolic acid in patients with active systemic vasculitides taking mycophenolate mofetil. Djabarouti S; Lazaro E; Breilh D; Pellegrin JL; Viallard JF J Rheumatol; 2012 Nov; 39(11):2222-3. PubMed ID: 23118295 [No Abstract] [Full Text] [Related]
2. Mycophenolate mofetil in the treatment of SLE and systemic vasculitis: experience at a single university center. Lourdudoss C; Vollenhoven Rv Lupus; 2014 Mar; 23(3):299-304. PubMed ID: 24399811 [TBL] [Abstract][Full Text] [Related]
4. Association between mycophenolic acid 12-h trough levels and clinical endpoints in patients with autoimmune disease on mycophenolate mofetil. Neumann I; Fuhrmann H; Fang IF; Jaeger A; Bayer P; Kovarik J Nephrol Dial Transplant; 2008 Nov; 23(11):3514-20. PubMed ID: 18586766 [TBL] [Abstract][Full Text] [Related]
5. Analysis on the infection among patients with nephrotic syndromes and systemic vasculitis treated with mycophenolate mofetil. Wang F; Wang N; Li J Clin Rheumatol; 2010 Sep; 29(9):1073-4. PubMed ID: 20490590 [No Abstract] [Full Text] [Related]
6. Treatment of primary systemic vasculitis with the inosine monophosphate dehydrogenase inhibitor mycophenolic acid. Hiemstra TF; Jones RB; Jayne DR Nephron Clin Pract; 2010; 116(1):c1-10. PubMed ID: 20484933 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of mycophenolate mofetil for the treatment of severely active lupus nephritis. Kittanamongkolchai W; Rukrung C; Supasiri T; Lertjirachai I; Somparn P; Chariyavilaskul P; Avihingsanon Y Lupus; 2013 Jun; 22(7):727-32. PubMed ID: 23651860 [TBL] [Abstract][Full Text] [Related]
8. Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients. Lam H; Jeffery J; Sitar DS; Aoki FY Ther Drug Monit; 2011 Dec; 33(6):699-704. PubMed ID: 22105586 [TBL] [Abstract][Full Text] [Related]
9. Mycophenolic acid trough level measurements and clinical outcomes in kidney transplantation recipients on a fixed dose (1.5 g/d) of mycophenolate mofetil in Korea. Lee S; Shin M; Kim E; Kim JM; Moon J; Jung G; Choi G; Kwon C; Joh J; Lee S; Kim S Transplant Proc; 2010 Apr; 42(3):793-6. PubMed ID: 20430174 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of mycophenolate mofetil in heart transplant recipients. Seebacher G; Mallinger R; Laufer G; Grimm M; Griesmacher A; Weigel G; Wolner E; Müller MM Adv Exp Med Biol; 1998; 431():801-3. PubMed ID: 9598174 [No Abstract] [Full Text] [Related]
11. Pharmacokinetics of mycophenolate sodium and comparison with the mofetil formulation in stable kidney transplant recipients. Cattaneo D; Cortinovis M; Baldelli S; Bitto A; Gotti E; Remuzzi G; Perico N Clin J Am Soc Nephrol; 2007 Nov; 2(6):1147-55. PubMed ID: 17928466 [TBL] [Abstract][Full Text] [Related]
12. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Sanquer S; Breil M; Baron C; Dhamane D; Astier A; Lang P Clin Pharmacol Ther; 1999 Jun; 65(6):640-8. PubMed ID: 10391669 [TBL] [Abstract][Full Text] [Related]
13. Trough blood concentrations in long-term treatment with mycophenolate mofetil. Sanquer S; Breil M; Baron C; Dahmane D; Astier A; Lang P Lancet; 1998 May; 351(9115):1557. PubMed ID: 10326544 [No Abstract] [Full Text] [Related]
14. Orofacial granulomatosis successfully treated with mycophenolate mofetil. Antonyan AS; Pena-Robichaux V; McHargue CA J Am Acad Dermatol; 2014 Jun; 70(6):e137-9. PubMed ID: 24831337 [No Abstract] [Full Text] [Related]
15. Pharmacokinetics and pharmacodynamics of mycophenolic acid after enteric-coated mycophenolate versus mycophenolate mofetil in patients with progressive IgA nephritis. Czock D; Rasche FM; Carius A; Glander P; Budde K; Bauer S; Keller F; von Müller L J Clin Pharmacol; 2007 Jul; 47(7):850-9. PubMed ID: 17526858 [TBL] [Abstract][Full Text] [Related]
16. Mycophenolic acid area under the curve correlates with disease activity in lupus patients treated with mycophenolate mofetil. Zahr N; Arnaud L; Marquet P; Haroche J; Costedoat-Chalumeau N; Hulot JS; Funck-Brentano C; Piette JC; Amoura Z Arthritis Rheum; 2010 Jul; 62(7):2047-54. PubMed ID: 20506558 [TBL] [Abstract][Full Text] [Related]
17. Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. Kaplan B Curr Med Res Opin; 2006 Dec; 22(12):2355-64. PubMed ID: 17257450 [TBL] [Abstract][Full Text] [Related]
19. Better mycophenolic acid 12-hour trough level after enteric-coated mycophenolate sodium in patients with gastrointestinal intolerance to mycophenolate mofetil. Sánchez Fructuoso A; Calvo N; Moreno MA; Giorgi M; Conesa J; Barrientos A Transplant Proc; 2007 Sep; 39(7):2194-6. PubMed ID: 17889135 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of mycophenolic acid after a single and multiple oral doses of mycophenolate mofetil in Chinese renal transplant recipients. Liang MZ; Lu YP; Nan F; Yu Q; Qin YP; Zou YG Transplant Proc; 2004 Sep; 36(7):2065-7. PubMed ID: 15518747 [No Abstract] [Full Text] [Related] [Next] [New Search]